Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson)

Invasive extraintestinal pathogenic E. coli disease (IED)

240K US cases/yr · $12.9B Global bacterial vaccines market 2024 (USD MM, Grand View Research) · 10000000 Global cases of invasive ExPEC disease annually

Disease Overview

Invasive extraintestinal pathogenic Escherichia coli disease (IED) refers to bloodstream, urosepsis, bacteremia and sepsis syndromes caused by ExPEC strains that migrate from the gut or urinary tract into normally sterile sites. A 2024-2025 CDC Emerging Infections Program surveillance study across nine US states estimated an overall invasive E. coli incidence of 74.7 per 100,000 population, with 67.9 bloodstream infections per 100,000 — implying roughly 240,000-250,000 US cases annually when projected to the full US population (~335M). Globally, ExPEC is estimated to cause approximately 10 million cases of invasive disease every year and is the single leading bacterial cause of sepsis in older adults, accounting for roughly 40% of all sepsis cases. The CDC found median patient age of 68, 57% female preponderance, >95% hospitalization rate and ~8% in-hospital mortality. The burden is concentrated in women, adults 60+ and Black patients, and is rising as antimicrobial-resistant ExPEC strains (particularly fluoroquinolone- and ESBL-resistant) expand. Despite four decades of attempts, no preventive ExPEC vaccine is approved anywhere in the world at the time of this deal.

Competitive Landscape

No approved preventive vaccine exists for invasive ExPEC disease at time of deal, making this a true first-in-class opportunity — but also a category graveyard. Clinical-stage candidates: ExPEC9V (VAC52416, 9-valent O-serotype bioconjugate, Janssen / Sanofi) was the most advanced asset, in Phase 3 E.mbrace at ~18,500 adults 60+ with recent UTI history, targeting bloodstream and urosepsis prevention. Its predecessor ExPEC4V (Janssen/GlycoVaxyn, 4-valent O1A/O2/O6A/O25B) advanced through Phase 2. Adjacent prevention mechanisms include FimH adhesin subunit vaccines (Sequoia Sciences' FimCH Phase 1b in recurrent UTI), whole-cell sublingual MV-140 (Uromune, Inmunotek, Phase 3 in Europe for recurrent UTI), and OM-89 / Uro-Vaxom (bacterial lysate, OM Pharma, marketed in EU as immunostimulant). No Big Pharma competitor has an approved invasive-disease ExPEC vaccine; Pfizer, GSK and MSD vaccines divisions have bacterial programs (pneumococcal, meningococcal, C. difficile) but no disclosed ExPEC Phase 3 asset. The class-defining precedent is Prevnar (Pfizer) in pneumococcal — a successful multivalent conjugate franchise, but ExPEC serotype coverage and antibody protection thresholds for bacteremia endpoints are less well established, which ultimately drove the February 2025 futility readout.